

Consolidated Income Statement

Year ended 31 December 2005

	Note	2005 HK\$'000	2004 HK\$'000 (Restated)
Continuing operations			
Turnover	6	1,481	47,334
Other revenue and gains		104	1,791
Raw materials and consumables used		(1,395)	(31,890)
Staff costs		(295)	(705)
Depreciation and amortisation		(2,921)	(7,473)
Gain on disposal of subsidiary		-	997
Gain arising from changes in fair value less estimated point-of-sale costs of biological assets	17	6,615	5,461
Provision for loss in cash deposit	24	-	(126,845)
Impairment on amount due from minority shareholder of a subsidiary		-	(20,529)
Write-off of computer software development cost	20	(5,208)	-
Write-off of property, plant and equipment	15	(1,990)	-
Provision for impairment of property, plant and equipment	15	(3,024)	-
Provision for impairment of goodwill	19	-	(40,513)
Impairment on receivables		(6,737)	(25,154)
Other operating expenses		(9,056)	(6,295)
Operating loss	8	(22,426)	(203,821)
Finance costs	9	(847)	(14)
Loss before income tax		(23,273)	(203,835)
Income tax expenses	10	-	-
Loss for the year from continuing operations		(23,273)	(203,835)
Discontinued operations			
Profit for the year from discontinued operations	7	-	5,290
Loss for the year		(23,273)	(198,545)
Loss attributable to:			
Equity holders of the Company	11	(23,273)	(165,419)
Minority interest		-	(33,126)
		(23,273)	(198,545)
Dividends			
		-	-
Loss per share attributable to the equity holders of the Company during the year			
- basic	12	(HK0.93 cents)	(HK4.40 cents)
- diluted		N/A	N/A